Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

8.935 -0.445 (-4.74%)
Streaming Delayed Price Updated: 1:15 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,965,993
Open 9.090
Bid (Size) 8.930 (7)
Ask (Size) 8.940 (6)
Prev. Close 9.380
Today's Range 8.800 - 9.267
52wk Range 5.950 - 62.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) INVESTOR ALERT Investors With Large Losses in MoonLake Immunotherapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-83.3%
-83.3%
1 Month
-83.2%
-83.2%
3 Month
-83.5%
-83.5%
6 Month
-76.7%
-76.7%
1 Year
-81.8%
-81.8%

More News

Read More
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Rosen Law Firm Urges MoonLake Immunotherapeutics (NASDAQ: MLTX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
From DJS Law Group
Via Business Wire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Which stocks have an unusual volume on Monday?
Via Chartmill
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
Via Benzinga
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake Immunotherapeutics (NASDAQ: MLTX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Unusual volume stocks are being observed in Friday's session.
Via Chartmill
Unusual volume stocks are being observed in Thursday's session.
Via Chartmill
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces Investigation into MoonLake Immunotherapeutics on Behalf of MoonLake Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
From DJS Law Group
Via Business Wire
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
From Rosen Law Firm
Via Business Wire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
Unusual volume stocks are being observed in Wednesday's session.
Via Chartmill
MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside
Via Stocktwits
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 8.935
When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 10/17/25 01:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.